<DOC>
	<DOCNO>NCT02375139</DOCNO>
	<brief_summary>This Phase I clinical study evaluate safety/tolerability pharmacokinetics DA-1229_01 ( Evogliptin/Metformin XR 2.5/500 mg x 2 tablet ) .</brief_summary>
	<brief_title>A Clinical Trial Investigate Safety/Tolerability Pharmacokinetics DA-1229_01 ( Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets ) Compared Co-administration Evogliptin 5 mg Metformin XR 1000 mg Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 19 45 , healthy male subject ( screen ) Body weight 55kg 90kg , BMI 18.0 27.0 FPG 60125mg/dL glucose level ( screen ) Volunteer totally understand progress clinical trial , make decision free , signed consent form follow progress . Volunteer past present history disease follow . ( liver include hepatitis virus carrier , kidney , Neurology , immunology , pulmonary , endocrine , hematooncology , cardiology , mental disorder ) Volunteer GI tract disease ( Crohn 's disease , ulcer , acute chronic pancreatitis ) surgery ( appendectomy , hernioplasty exclude ) Volunteer drug ( Aspirin , antibiotic ) hypersensitivity reaction Subject already participate trial 2 month Subject whole blood donation 2 month , component blood donation 1 month transfusion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>